SVANQEL
DEAD

Serial Number

79233966

Owner

NOVARTIS AG

Filing Date

Mar 24, 2018

Add to watchlist:

No watchlists yet
View on USPTO

SVANQEL Trademark

Serial Number: 79233966

SVANQEL is a trademark filed by NOVARTIS AG on March 24, 2018. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

NOVARTIS AG (7,171 trademarks)

CH-4002
BASEL , CH

Entity Type: 03

Trademark Details

Filing Date

March 24, 2018

Registration Date

Not Registered

Goods & Services

Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma

Filing History

DEATH OF INTERNATIONAL REGISTRATION
Jul 17, 2025 DETH
NOTIFICATION PROCESSED BY IB
Sep 25, 2022 GPNX
NOTIFICATION PROCESSED BY IB
May 30, 2022 GPNX
NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
May 6, 2022 DENA
DEATH OF INTERNATIONAL REGISTRATION
May 5, 2022 DETH
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
May 5, 2022 CORR
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
May 4, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
May 4, 2022 OP2R
NOTICE OF PUBLICATION
May 4, 2022 NPUB
ATTORNEY REVIEW COMPLETED
Apr 20, 2022 ATRV
ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED
Apr 18, 2022 ATRQ
REG. CANCELLED - RESTORED TO PENDENCY
Mar 7, 2022 CRTP
ASSIGNED TO PETITION STAFF
Feb 28, 2022 APET
REQUEST TO CANCEL INADVERTENTLY ISSUED REGISTRATION RECEIVED
Feb 23, 2022 RCII
NOTIFICATION PROCESSED BY IB
Dec 28, 2018 GPNX
CORRECTION TRANSACTION RECEIVED FROM IB
Dec 20, 2018 CRCV
FINAL DISPOSITION NOTICE SENT TO IB
Dec 2, 2018 FICS
FINAL DISPOSITION PROCESSED
Dec 2, 2018 FIMP
GRANT OF PROTECTION CREATED, TO BE SENT TO IB
Nov 15, 2018 GPAR
REGISTERED-PRINCIPAL REGISTER
Oct 16, 2018 R.PR
PUBLISHED FOR OPPOSITION
Jul 31, 2018 PUBO
NOTICE OF PUBLICATION
Jul 11, 2018 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 27, 2018 CNSA
ASSIGNED TO EXAMINER
Jun 26, 2018 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 16, 2018 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 12, 2018 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jun 11, 2018 LIMI
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Jun 7, 2018 SDRC